Cargando…

Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia

Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the functionally distinct leukemia stem cell (LSC) population, which is postulated to be responsible for disease resistance and relapse. We have previousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dorrance, Adrienne M., Neviani, Paolo, Ferenchak, Greg J., Huang, Xiaomeng, Nicolet, Deedra, Maharry, Kati S., Ozer, Hatice G, Hoellarbauer, Pia, Khalife, Jihane, Hill, Emily B., Yadav, Marshleen, Bolon, Brad N., Lee, Robert J., Lee, L.James, Croce, Carlo M., Garzon, Ramiro, Caligiuri, Michael A., Bloomfield, Clara D., Marcucci., Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633325/ https://www.ncbi.nlm.nih.gov/pubmed/26055302 http://dx.doi.org/10.1038/leu.2015.139

Ejemplares similares

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism
por: Rech, Monika, et al.
Publicado: (2018)

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2020)

Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models
por: Murdaca, Giuseppe, et al.
Publicado: (2019)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2021)

AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm
por: Gangemi, Sebastiano, et al.
Publicado: (2021)

AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
por: Kazemi, Azam, et al.
Publicado: (2021)

AntagomiR‐29b inhibits vascular and valvular calcification and improves heart function in rats
por: Fang, Ming, et al.
Publicado: (2020)

A novel biologically hierarchical hydrogel with osteoblast precursor‐targeting extracellular vesicles ameliorates bone loss in vivo via the sequential action of antagomiR‐200b‐3p and antagomiR‐130b‐3p
por: Dai, Hanhao, et al.
Publicado: (2023)

Exosomal Delivery of AntagomiRs Targeting Viral and Cellular MicroRNAs Synergistically Inhibits Cancer Angiogenesis
por: Wang, Jianguo, et al.
Publicado: (2020)

Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus
por: Guo, Hui, et al.
Publicado: (2023)

Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells
por: McCully, Mark, et al.
Publicado: (2018)

AntagomiR-451 inhibits oxygen glucose deprivation (OGD)-induced HUVEC necrosis via activating AMPK signaling
por: Yang, Xi, et al.
Publicado: (2017)

Enhanced effects of antagomiR-3074-3p-conjugated PEI-AuNPs on the odontogenic differentiation by targeting FKBP9
por: Jiang, Tao, et al.
Publicado: (2023)

Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the MLL gene
por: Bill, Marius, et al.
Publicado: (2021)

Delivery of antagomiR204-conjugated gold nanoparticles from PLGA sheets and its implication in promoting osseointegration of titanium implant in type 2 diabetes mellitus
por: Liu, Xiangwei, et al.
Publicado: (2017)

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia
por: Bill, Marius, et al.
Publicado: (2020)

Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis
por: Wang, Jianguo, et al.
Publicado: (2023)

Use of AgomiR and AntagomiR technologies to alter satellite cell proliferation in vitro, miRNA expression, and muscle fiber hypertrophy in intrauterine growth-restricted lambs
por: Greene, M. A., et al.
Publicado: (2023)

Targeting miR-126 in Ph+ acute lymphoblastic leukemia
por: Qiao, Junjing, et al.
Publicado: (2023)

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis
por: van Solingen, Coen, et al.
Publicado: (2009)

Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia
por: Zhang, Bin, et al.
Publicado: (2018)

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance
por: Zhang, Lianjun, et al.
Publicado: (2021)

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia
por: Ngankeu, Apollinaire, et al.
Publicado: (2017)

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
por: Niederwieser, Christian, et al.
Publicado: (2014)

Identification of Medium-Sized Copy Number Alterations in Whole-Genome Sequencing
por: Ozer, Hatice Gulcin, et al.
Publicado: (2015)

Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia
por: Huang, Xiaomeng, et al.
Publicado: (2016)

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023)

Antagomirbase- a putative antagomir database
por: Ganguli, Sayak, et al.
Publicado: (2011)

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
por: Papaioannou, Dimitrios, et al.
Publicado: (2017)

Specificity, duplex degradation and subcellular localization of antagomirs
por: Krützfeldt, Jan, et al.
Publicado: (2007)

Human ILC1s target leukemia stem cells and control development of AML
por: Caligiuri, Michael, et al.
Publicado: (2023)

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
por: Whitman, Susan P., et al.
Publicado: (2013)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
por: Mrózek, Krzysztof, et al.
Publicado: (2019)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

A precision medicine classification for treatment of acute myeloid leukemia in older patients
por: Mims, Alice S., et al.
Publicado: (2021)

Global proteomics dataset of miR-126 overexpression in acute myeloid leukemia
por: Schoof, Erwin M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m44vo5s53gts747nv4uhq4i0mf